Genomes For The Clinic

Personalized Medicine

The goal of personalized medicine is to achieve optimal therapy for each patient based on his or her genomic profile. In infectious or host-dependent diseases, this means therapies that also take into account the pathogen’s mutating genotype.

Single Genome Testing

In order to overcome genotyping limitations of current PCR-based tests for Hepatitis C (HCV) and the influenza virus, FUSION GENOMICS developed two single genome tests. Both tests provide the comprehensive genomic information necessary for pathogen genotyping of HCV and Influenza.
The ONETest HCV was specifically developed for genotyping highly mutated strains of the HCV virus and/or where multiple dominant and secondary genotype infections are also present.
The ONETest Influenza Sentinel focuses on a) the surveillance of influenza, due to the pandemic potential of flu and b) reducing the complexity of  current influenza genotype testing standards which require up to 22 different tests, have difficulty in characterizing rare genotypes and often fail in cases where the virus has acquired too many mutations.

Syndromic Genomic Panels

Respiratory tract infections are caused by a large number of viral, bacterial, and fungal pathogens, which all produce overlapping symptoms. Because current tests are pathogen driven, they require multiple testings to achieve accurate diagnosis. Even when successful, these test provide limited genetic information.
FUSION GENOMICS is developing a Multiplex Upper Respiratory ONETest (MURONTest) based on specifications by Key Opinion Leaders from Canada, EU and the pharmaceutical industry. The test is expected to detect over 25 pathogens with more than 100 subtypes and provide key information on genomic regions of interest for diagnosis, antibiotic resistance, detection of virulent strains and vaccine development.

Partial list of Pathogens Detected by Multiplex Upper Respiratory ONETest